Job Watch

EMBL: Group Leader

New Scientist - Bioinformatics - Tue, 2021-02-23 02:53
Competitive Salary: EMBL: About this position EMBL's European Bioinformatics Institute (EMBL-EBI) is seeking talented scientists to join its faculty to develop their own ind Hinxton, Cambridgeshire, England
Categories: Job Watch

EMBL: Group Leader

New Scientist - Bioinformatics - Tue, 2021-02-23 02:53
Competitive Salary: EMBL: About this position EMBL's European Bioinformatics Institute (EMBL-EBI) is seeking talented scientists to join its faculty to develop their own ind Hinxton, Cambridgeshire, England
Categories: Job Watch

Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Resource and Coordinating Center (U24 Clinical Trial Required)

Funding Opportunity RFA-HL-22-008 from the NIH Guide for Grants and Contracts. This FOA runs in parallel with the companion FOA (RFA-HL-22-007). This FOA uses the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism (UG3/UH3), and runs in parallel with a companion FOA (RFA-HL-22-008), which seeks applications for a Data Coordinating Center (DCC). Awards made under this FOA will support a milestone-driven planning phase, including feasibility studies and pilot trials for up to 2 years, with possible transition to an implementation phase (UH3) for up to five additional years. Only UG3 trials that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases. Applications must include plans for project management, subject recruitment and retention, scientific conduct of the trial including its design, randomization and power analysis; intervention, measurement, and statistical analysis of study results. Performance-based milestones must be included in each phase.

Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Clinical Centers (Collaborative UG3/UH3 Clinical Trial Required)

Funding Opportunity RFA-HL-22-007 from the NIH Guide for Grants and Contracts. This FOA uses the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism (UG3/UH3), and runs in parallel with a companion FOA (RFA-HL-22-008), which seeks applications for a Data Coordinating Center (DCC). Awards made under this FOA will support a milestone-driven planning phase, including feasibility studies and pilot trials for up to 2 years, with possible transition to an implementation phase (UH3) for up to five additional years. Only UG3 trials that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases. Applications must include plans for project management, subject recruitment and retention, scientific conduct of the trial including its design, randomization and power analysis; intervention, measurement, and statistical analysis of study results. Performance-based milestones must be included in each phase.

Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)

Funding Opportunity RFA-DK-21-005 from the NIH Guide for Grants and Contracts. This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.

ASSOC GROUP LEADER - PPD - Middleton, WI

Indeed.com - Bioinformatics - Fri, 2021-02-19 12:37
Bachelor’s degree in Chemistry, Pharmaceutical Manufacturing, Pharmaceutical Science, or another closely-related physical science and Six (6) years’ experience…
From PPD - Fri, 19 Feb 2021 17:37:01 GMT - View all Middleton, WI jobs
Categories: Job Watch

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

Funding Opportunity RFA-CA-21-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-21-007 from the NIH Guide for Grants and Contracts. To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.

EMBL: Senior Java Developer (FIRE)

New Scientist - Bioinformatics - Fri, 2021-02-19 05:03
Competitive Salary: EMBL: About this position We are seeking to recruit an enthusiastic, highly motivated senior software developer to work on the UK Biobank EMBLEM project Hinxton, Cambridgeshire, England
Categories: Job Watch

EMBL: Scientific Programmer

New Scientist - Bioinformatics - Fri, 2021-02-19 05:03
Competitive Salary: EMBL: About this position Ensembl is one of the leading providers of genome annotation. We seek a highly motivated, talented and experienced developer to Hinxton, Cambridgeshire, England
Categories: Job Watch

EMBL: Project Coordination Officer - European Genome-phenome Archive

New Scientist - Bioinformatics - Fri, 2021-02-19 05:03
Competitive Salary: EMBL: About this position The European Bioinformatics Institute (EMBL-EBI) is seeking a Project Coordination Officer to join the European Genome-phenome Hinxton, Cambridgeshire, England
Categories: Job Watch

EMBL: Bioinformatics Community Project Manager

New Scientist - Bioinformatics - Fri, 2021-02-19 05:03
Competitive Salary: EMBL: About this position The Zeller Team is looking for a community project manager to join the Bio-IT core team. The EMBL Bio-IT project aims to build Germany (DE)
Categories: Job Watch

EMBL: Lead Data Scientist/Bioinformatician - Biomedical data integration

New Scientist - Bioinformatics - Fri, 2021-02-19 05:03
Competitive Salary: EMBL: About this position The European Bioinformatics Institute (EMBL-EBI) is seeking to recruit a highly motivated Lead Data Scientist/Bioinformatician Hinxton, Cambridgeshire, England
Categories: Job Watch

Pages

Subscribe to Anil Jegga aggregator - Job Watch